OBJECTIVE: Deficiency of adenosine deaminase 2 (DADA2) is a potentially fatal monogenic syndrome characterized by variable manifestations of systemic vasculitis, bone marrow failure, and immunodeficiency. Most cases are diagnosed by pediatric care providers, given the typical early age of disease onset. This study was undertaken to describe the clinical phenotypes and treatment response both in adults and in children with DADA2 in India. METHODS: A retrospective analysis of pediatric and adult patients with DADA2 diagnosed at various rheumatology centers across India was conducted. Clinical characteristics, diagnostic findings, and treatment responses were analyzed in all subjects. RESULTS: In total, 33 cases of DADA2 were confirmed in this cohort between April 2017 and March 2020. Unlike previous studies, nearly one-half of the confirmed cases presented during adulthood. All symptomatic patients exhibited features of vasculitis, whereas constitutional symptoms and anemia were more common in pediatric patients. Cutaneous and neurologic involvement were common, and 18 subjects had experienced at least one stroke. In addition, the clinical spectrum of DADA2 was expanded by recognition of novel features in these patients, including pancreatic infarction, focal myocarditis, and diffuse alveolar hemorrhage. Treatment with tumor necrosis factor inhibitors (TNFi) was initiated in 25 patients. All of the identified disease manifestations showed marked improvement after initiation of TNFi, and disease remission was achieved in 19 patients. Two cases were complicated by tuberculosis infection, and 2 deaths were reported. CONCLUSION: This report presents the first case series of patients with DADA2 from India, diagnosed by adult and pediatric care providers. The findings raise awareness of this syndrome, particularly with regard to its presentation in adults.
OBJECTIVE: Deficiency of adenosine deaminase 2 (DADA2) is a potentially fatal monogenic syndrome characterized by variable manifestations of systemic vasculitis, bone marrow failure, and immunodeficiency. Most cases are diagnosed by pediatric care providers, given the typical early age of disease onset. This study was undertaken to describe the clinical phenotypes and treatment response both in adults and in children with DADA2 in India. METHODS: A retrospective analysis of pediatric and adult patients with DADA2 diagnosed at various rheumatology centers across India was conducted. Clinical characteristics, diagnostic findings, and treatment responses were analyzed in all subjects. RESULTS: In total, 33 cases of DADA2 were confirmed in this cohort between April 2017 and March 2020. Unlike previous studies, nearly one-half of the confirmed cases presented during adulthood. All symptomatic patients exhibited features of vasculitis, whereas constitutional symptoms and anemia were more common in pediatric patients. Cutaneous and neurologic involvement were common, and 18 subjects had experienced at least one stroke. In addition, the clinical spectrum of DADA2 was expanded by recognition of novel features in these patients, including pancreatic infarction, focal myocarditis, and diffuse alveolar hemorrhage. Treatment with tumor necrosis factor inhibitors (TNFi) was initiated in 25 patients. All of the identified disease manifestations showed marked improvement after initiation of TNFi, and disease remission was achieved in 19 patients. Two cases were complicated by tuberculosis infection, and 2 deaths were reported. CONCLUSION: This report presents the first case series of patients with DADA2 from India, diagnosed by adult and pediatric care providers. The findings raise awareness of this syndrome, particularly with regard to its presentation in adults.
Authors: Andrey V Zavialov; Eduard Gracia; Nicolas Glaichenhaus; Rafael Franco; Anton V Zavialov; Grégoire Lauvau Journal: J Leukoc Biol Date: 2010-05-07 Impact factor: 4.962
Authors: Eric F Pettersen; Thomas D Goddard; Conrad C Huang; Gregory S Couch; Daniel M Greenblatt; Elaine C Meng; Thomas E Ferrin Journal: J Comput Chem Date: 2004-10 Impact factor: 3.376
Authors: Qing Zhou; Dan Yang; Amanda K Ombrello; Andrey V Zavialov; Camilo Toro; Anton V Zavialov; Deborah L Stone; Jae Jin Chae; Sergio D Rosenzweig; Kevin Bishop; Karyl S Barron; Hye Sun Kuehn; Patrycja Hoffmann; Alejandra Negro; Wanxia L Tsai; Edward W Cowen; Wuhong Pei; Joshua D Milner; Christopher Silvin; Theo Heller; David T Chin; Nicholas J Patronas; John S Barber; Chyi-Chia R Lee; Geryl M Wood; Alexander Ling; Susan J Kelly; David E Kleiner; James C Mullikin; Nancy J Ganson; Heidi H Kong; Sophie Hambleton; Fabio Candotti; Martha M Quezado; Katherine R Calvo; Hawwa Alao; Beverly K Barham; Anne Jones; James F Meschia; Bradford B Worrall; Scott E Kasner; Stephen S Rich; Raphaela Goldbach-Mansky; Mario Abinun; Elizabeth Chalom; Alisa C Gotte; Marilynn Punaro; Virginia Pascual; James W Verbsky; Troy R Torgerson; Nora G Singer; Timothy R Gershon; Seza Ozen; Omer Karadag; Thomas A Fleisher; Elaine F Remmers; Shawn M Burgess; Susan L Moir; Massimo Gadina; Raman Sood; Michael S Hershfield; Manfred Boehm; Daniel L Kastner; Ivona Aksentijevich Journal: N Engl J Med Date: 2014-02-19 Impact factor: 91.245
Authors: Tania M Gonzalez Santiago; Andrey Zavialov; Janna Saarela; Mikko Seppanen; Ann M Reed; Roshini S Abraham; Lawrence E Gibson Journal: JAMA Dermatol Date: 2015-11 Impact factor: 10.282
Authors: Kristen M Gibson; Kimberly A Morishita; Paul Dancey; Paul Moorehead; Britt Drögemöller; Xiaohua Han; Jinko Graham; Robert E W Hancock; Dirk Foell; Susanne Benseler; Rashid Luqmani; Rae S M Yeung; Susan Shenoi; Marek Bohm; Alan M Rosenberg; Colin J Ross; David A Cabral; Kelly L Brown Journal: Arthritis Rheumatol Date: 2019-08-26 Impact factor: 10.995
Authors: Satish V Khadilkar; Chetan R Chaudhari; Rashna S Dastur; Pradnya S Gaitonde; Jayendra G Yadav Journal: Ann Indian Acad Neurol Date: 2016 Jan-Mar Impact factor: 1.383
Authors: Hyuk Jee; Zhengping Huang; Samantha Baxter; Yuelong Huang; Maria L Taylor; Lauren A Henderson; Sofia Rosenzweig; Aman Sharma; Eugene P Chambers; Michael S Hershfield; Qing Zhou; Fatma Dedeoglu; Ivona Aksentijevich; Peter A Nigrovic; Anne O'Donnell-Luria; Pui Y Lee Journal: J Allergy Clin Immunol Date: 2021-05-15 Impact factor: 10.793
Authors: Smruti Babtiwale; Venugopalan Y Vishnu; Ajay Garg; Vinay Goyal; Mamta B Singh; M V Padma Srivastava Journal: Ann Indian Acad Neurol Date: 2021-05-21 Impact factor: 1.383
Authors: Hasan Hashem; Giorgia Bucciol; Seza Ozen; Sule Unal; Ikbal Ok Bozkaya; Nurten Akarsu; Mervi Taskinen; Minna Koskenvuo; Janna Saarela; Dimana Dimitrova; Dennis D Hickstein; Amy P Hsu; Steven M Holland; Robert Krance; Ghadir Sasa; Ashish R Kumar; Ingo Müller; Monica Abreu de Sousa; Selket Delafontaine; Leen Moens; Florian Babor; Federica Barzaghi; Maria Pia Cicalese; Robbert Bredius; Joris van Montfrans; Valentina Baretta; Simone Cesaro; Polina Stepensky; Neven Benedicte; Despina Moshous; Guillaume Le Guenno; David Boutboul; Jignesh Dalal; Joel P Brooks; Elif Dokmeci; Jasmeen Dara; Carrie L Lucas; Sophie Hambleton; Keith Wilson; Stephen Jolles; Yener Koc; Tayfun Güngör; Caroline Schnider; Fabio Candotti; Sandra Steinmann; Ansgar Schulz; Chip Chambers; Michael Hershfield; Amanda Ombrello; Jennifer A Kanakry; Isabelle Meyts Journal: J Clin Immunol Date: 2021-07-29 Impact factor: 8.542